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Introduction and Background 
 
As a result of advances in genetics and medical informatics, new types of research are underway.  
Large predictive health projects are being undertaken that combine health data from medical records 
with genomic data analyzed from DNA, tissue or blood samples to identify genetic and 
environmental factors associated with health and disease.  Such studies aim to predict the risks 
associated with disease onset, and in so doing, to better prevent and treat disease. Many predictive 
health projects require researchers to obtain human biological materials that can be stored for 
immediate or later use and then linked to detailed health information from medical records, and 
other data from surveys. 
 
Increasingly, predictive health studies proceed through partnerships with multiple institutions and 
businesses, and with collaborators across the country and around the world. These arrangements are 
designed to maximize both scientific and commercial use, and to speed the translation of knowledge 
into enhanced patient care. Inherent in such arrangements are issues about ownership/sharing of 
data and materials, conflicts of interest, priority setting and benefit sharing. Several ethical issues 
arise: 
• Informed Consent – How much information should subjects receive, and how can researchers 
assess their understanding?  Can subjects give consent for future, unspecified uses of their 
samples?  Under what conditions should subjects be re-contacted for further studies? 
• Returning Health Information to Patients – Under what conditions should research conclusions be 
given to subjects?  Is it ever necessary to give information that has no diagnostic or therapeutic 
relevance?  Is there ever a moral obligation to inform subjects of the test results in predictive 
health studies? 
• Management of Genetic Privacy - Are current legal and social protections for individual privacy and 
confidentiality adequate?  If not, what additional protections are necessary? 
• Ownership and Commercialization – What rights do donors have to share in and control discoveries 
made with their tissues or health information?  What rights should they have?  
 
Successful predictive health research requires willing participants, public support, and equitable 
regulatory provisions. Robust participation should neither be assumed nor expected if scientists fail 
to fully engage the public in meaningful ways about the goals and methods of predictive health 
research and the implications of this research for individuals and society.  Factors that may 
discourage an engaged, supportive community include the following: 
 
• Loss of Privacy - Fear of improper disclosure of information to employers, insurance providers, 
and others. 
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• Discrimination - Fear of genetic or health-related discrimination or worries about social stigma and 
ethnic "profiling". 
• Commercialization - Concerns that current or future research will result in inequitable profits and 
access to care 
• Unanticipated Consequences - Concerns that research will diverge from the original expectations or 
principle values of the participant. 
• Safety and Trust - Public distrust following research scandals or bad press, examples include gene 
therapy deaths, health information security breaches, misuse of samples, and cloning fraud. 
• Frustration - Lengthy or complicated research protocols and procedures. 




Expert Panel Goals 
 
On November 2, 2007, the Indiana University Center for Bioethics convened an expert panel on 
predictive health research (PHR) as part of the Center’s Program in Predictive Health Ethics 
Research (http://www.bioethics.iu.edu/predicter.asp) which is supported by a grant from the 
Richard M. Fairbanks Foundation. The goal of this meeting was to identify the major obstacles and 
opportunities for engaging the community in PHR. PredictER intends to use the results of this 
meeting as a first step toward more fully engaging the Indianapolis community in discussions about 
PHR. We have deliberately avoided defining “community” since the term can be applied to a variety 
of demographic groups including those defined by age, (e.g.,  the aging community, the pediatric 
community), cultural and ethnic status (e.g., the African American community, the Ashkenazi Jewish 
community), and disease (e.g., the breast cancer community, the community of people living with 
HIV/AIDS). This focus on engaging the public is a key feature of PredictER, a program which 
ultimately seeks to develop the capacity for open, community-wide discussion about PHR and its 





The expert panel consisted of predictive health researchers in the Indiana University community.  
Because we were interested in portraying a broad spectrum of research interests, we specifically 
sought presenters and participants from several major disease, age, and population research 
initiatives. In addition to the presenters, the larger group of attendees was comprised of 
approximately 40 professionals from several specialties and research interests.  We took the constant 
and productive crosstalk between different fields, researchers, and community advocates as a marker 
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Session I used three case studies of current predictive health  studies being conducted by researchers 
at Indiana University: pediatric obesity (Laura Haneline), breast cancer (Anna Maria Storniolo and 
Connie Rufenbarger), and neurodegenerative disease (Tatiana Foroud and Leo Rafail).  These three 
cases were selected for two reasons: first, they represented a logical spectrum of disease from early 
life, to adulthood, to old age. Second, they were each at different stages of development: the 
pediatric obesity project was in the early design phase, whereas the Huntington’s Disease roster (the 
example from neurodegenerative disease) has been in operation for more than 25 years. All of the 
researchers were asked to present an overview of their work along with a community advocate with 
whom they have been working. This allowed the panel to expand the scope of each presentation to 
include how this research/community collaboration was built, and what obstacles, if any, were 
overcome.  To illustrate the later point, the pediatric obesity project has not yet identified its key 
community contact.  Panel presentations were 30 minutes followed by a 15 minute session for 
questions and answers. 
 
Session II provided a brief review of the current academic and public understanding of the ethical 
issues in predictive health research. The second section aimed to provide a follow-up on the 
predictive health presentations in the first session and to prime the group of experts to extend the 
current state of research in predictive health further.  Following Jere Odell’s overview of the 
literature on ethical issues (N = 1400 articles), five PredictER-funded researchers addressed the 
audience.  Three of the presentations focused on empirical data and sought to understand the 
knowledge and attitudes of predictive health research participants and stakeholders, including: health 
professionals (Jody Harland), pregnant women (David Haas), and the general public (Jim Wolf). A 
fourth presentation focused on legal and regulatory issues (Jenny Girod). A summary of the evident 
“gaps” in knowledge was presented (Peter Schwartz).  
 
Session III used a modified nominal group process (MNGP)1 with three groups to identify the most 
pressing issues in predictive health with respect to community engagement. Each group was lead by 
a facilitator (Wolf, Quaid, Schwartz), and a student recorder. After randomly assigning participants, 
the three groups were adjusted to ensure that sufficient multi-disciplinarity was achieved. The 
MNGP occurred as follows: 
• Participants were asked to silently list the most important issues and then share each of these 
issues in a group roundtable report.  No judgment for or against any individual’s ideas was 
allowed; similarly limited clarification of ideas was sought until a complete list had been 
elicited.  Inspiration and brainstorming following from the ideas of fellow group members 
were encouraged. 
• Once a complete list had been generated, group facilitators sought to clarify, divide, and/or 
combine ideas.   
• After the group was satisfied with the list’s appearance, individuals were asked to vote on 
ideas based on the importance of the idea with respect to engaging the community.  Voting 
based on an issue’s solvability or simplicity was discouraged.  
• Lastly, the ideas which were judged most important were then opened for a discussion of 
solvability.   
 
3 
                                                 
1 Delbecq AL, Van de Ven AH, Gustafson DH. Group Techniques for Program Planning: A Guide to Nominal 
Group and Delphi Processes. Glenview: Scott Foresman, 1975. 
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The end product of the third session was a non-uniform list of issues key in PHR and public 
engagement. 
 
Session IV brought all panel members together again to present the small group results and to work 
toward a greater understanding of the issues of predictive health research and public involvement.  
The fourth session was a forum for open discussion moderated by another predictive health 





The goal of reaching a non-uniform collection of issues was achieved.  On average, groups 
generated approximately 50 different issues to vote on, and while some groups were able to 
successfully combine similar ideas into larger themes, other groups found more success in remaining 
with their initial issues and voting on these.  Groups selected the top issues by looking for a bimodal 
representation of point totals in the voting.  The findings were: 
 
Group 1 
• Trust between research and community  
• Providing incentives and motivations to participate 
• Identification and involvement of community leaders 
• Convincing community of the significance of health problems and possibility of impact 
• Education on research topic 
• Openly listening to community partners 
• Open dialogue between researchers and community 
• Distilling the public health message 
• Engendering partnership and shared enthusiasm 
• Addressing any ethnic disparities between researchers and the community 
 
Group 2 
• Strategies for engagement 
• Educating researchers 
• Shared vision  
 
Group 3 
• What’s the message? 
• Defining communities 
• Target communities 
• Understanding how the community wants to help 
• Articulating the goals of engagement 
 
 
The result of the final plenary session was a presentation of these ideas by each group along with a 
discussion to determine if different groups were saying the same thing or if the nuances in wording 
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actually reflected a larger thematic difference in each groups’ understanding.  Our findings were that 
the latter, small differences in wording, actually reflected overall differences in groups’ 
understandings of predictive health and public engagement.  
 
For example, Group 2 identified a “shared vision” as an important issue, and Group 3 asked 
“What’s the message?”  While it was agreed that both points drew attention to the need for clear and 
consistent communication with the public, further discussion revealed that the group that asked 
about the “message”  was actually seeking to clarify what researchers would convey to the public 
about PHR, whereas the group that focused on  “vision” was more interested in how the message 
was derived; that is, will the message be  the result of a vision shared by both researchers and 
participants, and will this shared vision be broadly marketable. Similarly, Group 1 provided a longer 
list of issues but chose to lump them into three large themes: how to create trust and partnership 
between researchers and the community; how to educate and motivate the community; and the need 
to address ethnic disparities between the community and researchers.  
 
Lastly, the plenary group discussion also examined what is meant by "community", whether it is a 
selected population with an interest in a certain disease, an ethnic group, or a general collection of 
persons interested in predictive health.  This question led to the comparison of an existing breast 
cancer biobank to a potential longitudinal study on multiple health risk factors.  While the breast 
cancer researchers and community have been able to make use of high profile fundraisers to further 
increase public awareness and to encourage tissue donation, the plenary group expected that a 
multiple health risk factor study would lack a single coordinated community or event, and would 
have notably greater difficulty garnering support and engaging in community conversation.  
 
 
Approaching the Community 
 
The differences noted in communities, in engagement, and in engendering trust all focus on how the 
community is approached.  Isolating a group of individuals and asking them to participate in a pre-
determined research protocol has limited potential for ongoing collaboration with the community.  
The best results are achieved when predictive health researchers view the community not as the 
subject of research but as a partner in bridging the gaps between disease and health. More clearly, 
the success of a predictive health research project cannot merely be measured by the number of 
specimens in a biobank, but must also be measured by the understanding, trust, and cooperation 
achieved between researcher and community.  Although a number of predictive health researchers 
were able to gather for a day of collaborative, interdisciplinary discussion, to identify a list of issues, 
and to begin to speculate on the how to solve them, PHR as a whole is still very far from 
successfully achieving a broad, public conversation on the benefits, concerns, and overall 
understanding of predictive health.  Thus, the next step for the PredictER program is to meet with 
community leaders with the goal of working toward an understanding of the concerns and 
opportunities they see for the role of predictive health within their own communities.
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